Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis.

Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lanctôt KL.

Can J Psychiatry. 2010 Feb;55(2):91-9.

PMID:
20181304
2.

Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.

Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson BL, Dorian P, Guertin MC; CREATE Investigators.

JAMA. 2007 Jan 24;297(4):367-79. Erratum in: JAMA. 2007 Jul 4;298(1):40.

PMID:
17244833
3.

Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.

Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A.

Health Technol Assess. 2013 Feb;17(7):1-166. doi: 10.3310/hta17070.

4.

Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis.

Thompson S, Herrmann N, Rapoport MJ, Lanctôt KL.

Can J Psychiatry. 2007 Apr;52(4):248-55.

PMID:
17500306
5.

A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.

Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.

J Clin Psychopharmacol. 2006 Dec;26(6):653-6.

PMID:
17110825
6.

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.

J Clin Psychiatry. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191. Erratum in: J Clin Psychiatry. 2011 Jun;72(6):874.

PMID:
21527123
7.
8.

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.

J Clin Psychiatry. 2012 Jul;73(7):984-91. doi: 10.4088/JCP.11m07230.

PMID:
22901348
9.

Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.

Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS.

JAMA. 2009 Oct 21;302(15):1651-7. doi: 10.1001/jama.2009.1487.

10.
11.
12.

Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression.

Isacsson G, Adler M.

Acta Psychiatr Scand. 2012 Jun;125(6):453-9. doi: 10.1111/j.1600-0447.2011.01815.x. Epub 2011 Dec 19.

PMID:
22176585
13.

Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.

Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI.

J Clin Psychiatry. 2011 Dec;72(12):1660-8. doi: 10.4088/JCP.10r06531.

PMID:
22244025
14.

Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.

Mazereeuw G, Herrmann N, Oh PI, Ma DW, Wang CT, Kiss A, Lanctôt KL.

J Clin Psychopharmacol. 2016 Oct;36(5):436-44. doi: 10.1097/JCP.0000000000000565.

15.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators.

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
16.

Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.

Ng CG, Boks MP, Roes KC, Zainal NZ, Sulaiman AH, Tan SB, de Wit NJ.

Eur Neuropsychopharmacol. 2014 Apr;24(4):491-8. doi: 10.1016/j.euroneuro.2014.01.016. Epub 2014 Jan 20.

PMID:
24503279
17.

A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression.

Lydiard RB, Stahl SM, Hertzman M, Harrison WM.

J Clin Psychiatry. 1997 Nov;58(11):484-91.

PMID:
9413414
18.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
19.

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.

Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ; Zoloft's Effects on Symptoms and survival Time Trial Group.

Lancet Oncol. 2007 Jul;8(7):603-12. Erratum in: Lancet Oncol. 2007 Jul 8;8(7):574.

PMID:
17548243
20.

Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.

Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ.

J Clin Psychiatry. 2013 Oct;74(10):966-73. doi: 10.4088/JCP.12m08252.

Supplemental Content

Support Center